StockData

Connect Biopharma vs Kyntra Bio

CNTB and KYNB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CNTB and KYNB compare

Connect Biopharma grew revenue faster over the last twelve months (50.3% versus −37.1% for Kyntra Bio).

Kyntra Bio keeps more of each dollar of sales as profit, with a net margin of 3968% compared with −2336% at Connect Biopharma.

Connect Biopharma scores higher on the StockData Score (6 against 5 for Kyntra Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCNTBKYNB
Size and price
Market cap–$13.9M
Share price$0.677$3.44
Change, 1 year−57.9%−62.3%
Change, 5 years−86.8%−98.9%
Beta (5Y)0.531.24
Employees–34
StockData Score
Total score6 (better)5
Valuation score02 (better)
Growth score1 (better)0
Performance score02 (better)
Health score5 (better)1
Dividend score00
Valuation
P/E–0.1×
P/S–3.0×
FCF yield–−273%
Growth
Revenue growth (TTM)50.3% (better)−37.1%
Revenue growth, 5Y average–−48.4%
Profitability
Gross margin–6.3%
Operating margin−2384%−1090% (better)
Net margin−2336%3968% (better)
FCF margin−2053%−824% (better)
Return on equity−141%–
Financial health
Debt / equity0.00–
Interest coverage–−5.4×
Current ratio2.372.69 (better)
Altman Z-score–−24.47
Piotroski F-score15 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions22.1%24.7%
Held by insiders31.6%15.7%
Insider net buying, 12 months$4.4M (better)$39.7K
Short interest, % of float–2.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.